ClinicalTrials.gg
CompletedNCT01635101Updated Jan 21, 2020Results posted

A Multi-Center Study of the Efficacy, Pharmacokinetics (PK) and Pharmacodynamics (PD) of IV Acetaminophen for the Treatment of Acute Pain in Pediatric Patients

A Phase 3 interventional study of IV Acetaminophen and IV Control in Acute Pain, sponsored by Mallinckrodt. Completed at 22 sites in United States. Open to participants aged 1 Day to 2 Years. Per ClinicalTrials.gov, last updated 2020-01-21.

Sponsored by Mallinckrodt · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
197
Allocation
Randomized
Ages
1 Day to 2 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing acetaminophen in Acute Pain — 1 open to participants now, 1 under way, none of them phase 3. Acetaminophen · Acute Pain.

Enrollment
10th of 21
197 · median 162
Started
2012
with 2 others
Phase 3
7 of 21
none open now
Registered
5th of 21
by date
Lead sponsor
2 of 21
Mallinckrodt

Among the 21 studies testing acetaminophen in Acute Pain, this one is the 10th largest by enrollment, is one of 3 that started in 2012, is one of 7 in phase 3, and was the 5th registered.

Acute Pain

1,075 studies on the registry are indexed under Acute Pain; 168 are open to participants now.

Browse Acute Pain studies →

Open to participants now

1 of the 21 studies testing acetaminophen in Acute Pain is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.

This study: 1 Day to 2 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing acetaminophen in Acute Pain, or all of them as a file.
02

Study summary

The purpose of this study is to demonstrate the efficacy and safety of Intravenous (IV) acetaminophen plus rescue opioids for the relief of moderate to severe acute pain in neonates and infants (age \< 2 years) compared to placebo plus standard of care rescue opioids as well as characterize the concentration-effect relationship (PK/PD) of the intravenous acetaminophen as compared to the control group.

03

Conditions studied

  • Acute Pain

Keywords

  • Moderate to severe acute pain following surgery or trauma
04

Who can participate

Ages eligible
1 Day to 2 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is ≥ 28 weeks gestational age and \< 2 years old at study enrollment
  • Subject will undergo surgery or had a traumatic injury expected to produce moderate to severe pain and patient is expected to require analgesic treatment for acute pain for 24 hours
  • Subject has a medically reasonable need for IV treatment due to their underlying procedure(s) or medical condition(s) for the duration of the study
  • Subject has reliable vascular access for administration of study medication and PK sampling
  • Subject has a bodyweight which, in the opinion of the Investigator does not preclude participation in the study.
  • Subject is free of other physical, mental, or medical conditions which, in the opinion of the Investigator, make study participation inadvisable or make it impossible to accurately assess efficacy or safety endpoints
  • Subject's parent or guardian must provide written prior to participation in the study
  • Subject's parent or guardian must have the ability to read and understand the study procedures and have the ability to communicate meaningfully with the study investigator and staff

Exclusion criteria

Exclusion Criteria:

  • Subject is not able to comply with the sampling requirements of the study
  • Subject has known or suspected to acetaminophen or the of IV acetaminophen
  • Subject has any significant medical condition that in the opinion of the Investigator contraindicates participation in the study or impairs the assessment of efficacy or safety
  • Subject has participated in another interventional clinical study within 30 days of the planned study randomization date

Pre-Randomization (Qualification) Inclusion Criteria

Subject has not been administered any of the following:

  • any acetaminophen-containing product, nonsteroidal anti-inflammatory agent, central alpha-adrenergic agents (e.g., clonidine, dexmedetomidine) or ketamine within 6 hours of baseline (T0)
  • received a regional or neuraxial (caudal, epidural or spinal) anesthetic with local anesthetics within 6 hours of T0
  • Subject does not have abnormal liver function tests from a sample obtained post-operatively/post-trauma and prior to randomization above protocol-specified limits
  • Subject does not have significantly impaired renal function or known significant renal disease which in the opinion of the Investigator would contraindicate study participation.
  • Subject had a nursing assessment documenting moderate to severe pain within 6 hours prior to randomization
  • Subject required at least one dose of parenteral opioid medication for pain management (i.e., not pre-emptive therapy) during the 6-hour pre-randomization period, and is anticipated to require at least one dose of parenteral opioid medication during the 24 hour treatment period
  • If subject is breast feeding, mother has not been administered any acetaminophen containing product in the previous 6 hours to T0 and throughout the treatment period
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
197 participants (actual)

Study arms

  • Experimental
    Low Dose Acetaminophen

    Participants receive a low dose of acetaminophen intravenously (IV) for 24 hours

    Drug: IV Acetaminophen

  • Experimental
    High Dose Acetaminophen

    Participants receive a low dose of acetaminophen (IV) for 24 hours

    Drug: IV Acetaminophen

  • Placebo comparator
    Placebo

    Participants receive matching placebo (IV) for 24 hours

    Drug: IV Control

Interventions

  • IV Acetaminophen given every 6 hours (q6h); 4 doses, in 24 hours

    Also known as: OFIRMEV

  • DrugIV Control

    IV Control q6h; 4 doses, in 24 hours

    Also known as: Saline, Placebo

06

What researchers measure

Primary outcomes

  1. Total Rescue Opioid Consumption

    Total micrograms per kilogram (µg/kg) of rescue opioid used during the same 24 hours the subject is on study medication

    Time frame: in 24 hours

Secondary outcomes

  1. Time to First Rescue Medication

    Time frame: within 24 hours

  2. Summary of Pain Intensity Using the Leuven Neonatal Pain Scale (LNPS) in Neonates

    The LNPS is used for assessing pain intensity in neonates. Scores on the scale run from 0-14. Higher scores mean worse pain.

    Time frame: within 24 Hours

  3. Summary of Pain Intensity Using the LNPS in Younger Infants

    The LNPS is used for assessing pain intensity in younger infants. Scores on the scale run from 0-14. Higher scores mean worse pain.

    Time frame: within 24 hours

  4. Pain Intensity Using the FLACC Score in Intermediate Aged Infants

    The Face, Leg, Activity, Cry, and Consolability (FLACC) scale is used to assess pain intensity in intermediate aged infants. The scale is scored in a range of 0-10 with 0 representing no pain. A higher score means more pain.

    Time frame: within 24 hours

  5. Pain Intensity Using the FLACC Score in Older Infants

    The FLACC scale is used to assess pain intensity in older infants. The scale is scored in a range of 0-10 with 0 representing no pain. A higher score means more pain.

    Time frame: within 24 hours

07

Results

Posted Jan 21, 2020

Participant flow

Participant flow — Overall Study
MilestoneLow Dose AcetaminophenHigh Dose AcetaminophenPlacebo
Started616769
Safety population616769
Modified intent to treat (mitt)616769
Pharmacokinetics evaluable population505958
Completed525552
Not completed91217

Outcome measures

PrimaryTotal Rescue Opioid Consumption

Total micrograms per kilogram (µg/kg) of rescue opioid used during the same 24 hours the subject is on study medication

Time frame:
in 24 hours
Reported as:
Mean · µg/kg
Total Rescue Opioid Consumption
µg/kgLow Dose AcetaminophenHigh Dose AcetaminophenPlacebo
Total Rescue Opioid Consumption166.9 ± 225.06179.9 ± 193.47180.2 ± 184.70
Statistical analysis
  • Low Dose Acetaminophen vs Placebo · ANOVA · p = 0.736 · Ls mean difference: -11.8 · 97.5% CI -91.0 to 67.3
  • High Dose Acetaminophen vs Placebo · ANOVA · p = 0.967 · Ls mean difference: 1.4 · 97.5% CI -75.9 to 78.7
SecondaryTime to First Rescue Medication
Time frame:
within 24 hours
Reported as:
Median · hours
Time to First Rescue Medication
hoursLow Dose AcetaminophenHigh Dose AcetaminophenPlacebo
Time to First Rescue Medication4.78 (3.15 to 16.32)4.76 (2.15 to 10.08)3.81 (2.25 to 8.95)
SecondarySummary of Pain Intensity Using the Leuven Neonatal Pain Scale (LNPS) in Neonates

The LNPS is used for assessing pain intensity in neonates. Scores on the scale run from 0-14. Higher scores mean worse pain.

Time frame:
within 24 Hours
Reported as:
Mean · score on a scale
Summary of Pain Intensity Using the Leuven Neonatal Pain Scale (LNPS) in Neonates
score on a scaleLow Dose AcetaminophenHigh Dose AcetaminophenPlacebo
at 0 hours0.8 ± 1.090.8 ± 1.271.1 ± 1.26
at 6 hours1.1 ± 1.041.0 ± 1.411.2 ± 1.82
at 12 hours2.2 ± 1.921.8 ± 1.762.0 ± 1.83
at 18 hours1.0 ± 1.531.8 ± 1.990.8 ± 0.99
at 24 hours0.8 ± 1.401.3 ± 1.420.9 ± 1.40
SecondarySummary of Pain Intensity Using the LNPS in Younger Infants

The LNPS is used for assessing pain intensity in younger infants. Scores on the scale run from 0-14. Higher scores mean worse pain.

Time frame:
within 24 hours
Reported as:
Mean · score on a scale
Summary of Pain Intensity Using the LNPS in Younger Infants
score on a scaleLow Dose AcetaminophenHigh Dose AcetaminophenPlacebo
at 0 hours2.1 ± 2.851.5 ± 1.852.2 ± 2.05
at 6 hours2.1 ± 2.361.3 ± 1.332.4 ± 3.10
at 12 hours2.2 ± 2.41.8 ± 1.581.9 ± 1.24
at 18 hours1.6 ± 2.251.7 ± 2.062.1 ± 1.44
at 24 hours2.3 ± 1.591.3 ± 1.632.9 ± 2.51
SecondaryPain Intensity Using the FLACC Score in Intermediate Aged Infants

The Face, Leg, Activity, Cry, and Consolability (FLACC) scale is used to assess pain intensity in intermediate aged infants. The scale is scored in a range of 0-10 with 0 representing no pain. A higher score means more pain.

Time frame:
within 24 hours
Reported as:
Mean · score on a scale
Pain Intensity Using the FLACC Score in Intermediate Aged Infants
score on a scaleLow Dose AcetaminophenHigh Dose AcetaminophenPlacebo
at 0 hours0.6 ± 1.301.6 ± 2.271.2 ± 2.05
at 6 hours0.7 ± 0.832.1 ± 2.711.4 ± 2.59
at 12 hours1.2 ± 1.410.08 ± 1.391.8 ± 2.49
at 18 hours1.4 ± 2.010.9 ± 1.190.5 ± 0.97
at 24 hours1.4 ± 2.290.9 ± 1.560.3 ± 0.65
SecondaryPain Intensity Using the FLACC Score in Older Infants

The FLACC scale is used to assess pain intensity in older infants. The scale is scored in a range of 0-10 with 0 representing no pain. A higher score means more pain.

Time frame:
within 24 hours
Reported as:
Mean · score on a scale
Pain Intensity Using the FLACC Score in Older Infants
score on a scaleLow Dose AcetaminophenHigh Dose AcetaminophenPlacebo
at 0 hours2.2 ± 2.641.8 ± 2.651.8 ± 2.37
at 6 hours0.5 ± 0.901.2 ± 2.071.5 ± 2.42
at 12 hours0.8 ± 1.271.7 ± 2.762.4 ± 1.78
at 18 hours1.3 ± 1.950.1 ± 0.361.3 ± 2.67
at 24 hours2.0 ± 2.590.8 ± 1.120.1 ± 0.29

Adverse events

Collected over 24 hours. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Dose Acetaminophen0/61 (0%)0/61 (0%)21/61 (34.4%)
High Dose Acetaminophen0/67 (0%)1/67 (1.5%)8/67 (11.9%)
Placebo0/69 (0%)2/69 (2.9%)24/69 (34.8%)
Most frequent serious events
Most frequent serious events
EventLow Dose AcetaminophenHigh Dose AcetaminophenPlacebo
ApneaRespiratory, thoracic and mediastinal disorders0/611/670/69
HypoxiaRespiratory, thoracic and mediastinal disorders0/610/671/69
LeucocytosisBlood and lymphatic system disorders0/610/671/69
Most frequent other events
Most frequent other events
EventLow Dose AcetaminophenHigh Dose AcetaminophenPlacebo
PyrexiaGeneral disorders3/613/6713/69
VomitingGastrointestinal disorders7/612/674/69
TachycardiaCardiac disorders0/610/676/69
Pleural effusionRespiratory, thoracic and mediastinal disorders5/610/673/69
ConstipationGastrointestinal disorders3/612/672/69
Body temperature increasedInvestigations3/610/670/69
HypokalaemiaMetabolism and nutrition disorders3/613/671/69

Baseline characteristics

Modified Intent-to-Treat (mITT) population

Age, Customized
Age, Customized(Participants)Low Dose AcetaminophenHigh Dose AcetaminophenPlaceboTotal
All Participants — Neonates (birth to ≤ 28 days)13121338
All Participants — Younger infants (≥ 29 days to < 6 mos)16201854
All Participants — Intermediate aged infants (≥ 6 mos to <12 mos)18172055
All Participants — Older infants (≥12 mos to <24 mos)14181850
Sex: Female, Male
Sex: Female, Male(Participants)Low Dose AcetaminophenHigh Dose AcetaminophenPlaceboTotal
Female17272670
Male444043127
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Low Dose AcetaminophenHigh Dose AcetaminophenPlaceboTotal
American Indian or Alaska Native1001
Asian34613
Native Hawaiian or Other Pacific Islander0000
Black or African American129930
White404946135
More than one race0000
Unknown or Not Reported55818
Region of Enrollment
Region of Enrollment(participants)Low Dose AcetaminophenHigh Dose AcetaminophenPlaceboTotal
United States616769197
08

Study locations

22 sites
  • Children's Of Alabama
    Birmingham, Alabama 35294, United States
  • Children's Hospital of Orange County
    Orange, California 92868, United States
  • Rady Children's Hosptial San Diego
    San Diego, California 92123, United States
  • Stanford University
    Stanford, California 94305, United States
  • Jackson Memorial Hospital
    Miami, Florida 33236, United States
  • Ann & Robert H. Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Mott Children's Hospital
    Ann Arbor, Michigan 48109, United States
  • Amplatz Children's Hospital
    Minneapolis, Minnesota 55455, United States
  • Kings County Hospital Center
    Brooklyn, New York 11203, United States
  • University of North Carolina-Chapel Hill
    Chapel Hill, North Carolina 27599, United States
  • Duke University
    Durham, North Carolina 27710, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Penn State Milton S. Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • The Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • Monroe Carell Jr. Children's Hospital at Vanderbilt
    Nashville, Tennessee 37232, United States
  • Children's Medical Center Dallas
    Dallas, Texas 75235, United States
  • Univ. of Texas Health Sciences Center
    Houston, Texas 77030, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Medical College of Wisconsin, Children's Hospital of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Publications

  • Hammer GB, Maxwell LG, Taicher BM, Visoiu M, Cooper DS, Szmuk P, Pheng LH, Gosselin NH, Lu J, Devarakonda K. Randomized Population Pharmacokinetic Analysis and Safety of Intravenous Acetaminophen for Acute Postoperative Pain in Neonates and Infants. J Clin Pharmacol. 2020 Jan;60(1):16-27. doi: 10.1002/jcph.1508. Epub 2019 Aug 25. PubMed 31448420 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2012, a primary completion of Aug 2015 and a completion of Nov 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2020, 4 years 5 months after primary completion. A results delay was requested in Aug 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2012
First posted
Jul 6, 2012
Start
Jun 2012
Primary completionActual
Aug 2015
CompletionActual
Nov 2015
Results delay requested
Aug 9, 2016
Results first posted
Jan 21, 2020
Last update
Jan 21, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01635101
Lead sponsor
Mallinckrodt
Responsible party
Sponsor
First posted
Jul 6, 2012
Start date
Jun 2012
Primary completion
Aug 2015
Completion
Nov 2015
Results posted
Jan 21, 2020
Last update
Jan 21, 2020

Study contacts

Clinical Team Leader
study director · Mallinckrodt

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion